Please amend the claims as follows:

Claim 1 (Previously Presented): An immunogenic peptide constituting a T epitope presented by MHC I, wherein said immunogenic peptide consists of a fragment of 8 to 11

consecutive amino acids of the Eck tyrosine kinase receptor (EphA2) protein.

Claim 2 (Previously Presented): The immunogenic peptide as claimed in claim 1,

wherein the immunogenic peptide is selected from the group consisting of:

- the peptide of sequence IMNDMPIYM (SEQ ID NO: 4);

- the peptide of sequence VLLLVLAGV (SEQ ID NO: 6);

- the peptide of sequence VLAGVGFFI (SEQ ID NO: 7); and

- the peptide of sequence TLADFDPRV (SEQ ID NO: 8).

Claim 3 (Previously Presented): An immunogenic peptide constituting a T epitope

presented by MHC I, wherein said immunogenic peptide is derived from a peptide consisting

of a fragment of 8 to 11 consecutive amino acids of the EphA2 protein, by substitution of at

least one amino acid of said peptide with an amino acid which increases the binding affinity

and/or the stability of said peptide for an MHC I allele compared to the unsubstituted peptide.

Claim 4 (Previously Presented): The immunogenic peptide as claimed in claim 3,

wherein said immunogenic peptide is derived from the peptide consisting of a fragment of 8

to 11 consecutive amino acids of the EphA2 protein, by substitution of the N-terminal amino

acid of said peptide with a tyrosine residue.

2

Application No. 10/511,273 Reply to Office Action of October 15, 2007

Claim 5 (Previously Presented): The immunogenic peptide as claimed in claim 4, wherein said immunogenic peptide has the sequence YMPIYMYSV (SEQ ID NO: 9).

Claim 6 (Canceled).

Claim 7 (Previously Presented): A composition comprising at least one peptide as claimed in claim 1.

Claims 8-29 (Cancelled)